Table 2. Studies which compare complete mesocolic excision with conventional surgery for colon cancer.
| First author/country/publishing year/reference | No. of patients | Overall complications (%) | Mortality (%) | No. of lymph nodes | Oncological outcomes |
|---|---|---|---|---|---|
| Gao, China, 2018 (1) | CME: 220 | 25 | 0.4 | 24 | 3-year LRR: 100%; 3-year OS: 97.2%; 3-year DFS: 92.2% |
| Non-CME: 110 | 17.2 | 0.9 | 20 | 3-year LRR: 90.2%; 3-year OS: 98.3%; 3-year DFS: 90% | |
| Agalianos, Greece, 2017 (9) | CME: 145 | – | 13.79 | 27 | 5-year OS: 81.3%; 5-year DFS: 84.6% |
| Non-CME: 145 | – | 24.31 | 18 | 5-year OS: 70.9%; 5-year DFS: 76.4% | |
| Bertelsen, Denmark, 2016 (10,11) | CME: 529 | 30.6 | 6.2 (90-day) | 36 | 5-year OS: 74.9%; 4-year DFS: 85.8% |
| Non-CME: 1701 | 28.5 | 4.9 (90-day) | 20 | 5-year OS: 69.8%; 4-year DFS: 73.4% | |
| Merkel, Germany, 2016 (12) | CME: 1099 | 21.3 | 2.7 | 25 | 5-year LRR: 1 (stage I, II); 4 (stage III) |
| 5-year OS: 83 (stage I, II); 69 (stage III) | |||||
| 5-year DSS: 95 (stage I, II); 81 (stage III) | |||||
| Non-CME: 429 | 17.2 | 3.7 | 25 | 5-year LRR: 2% (stage I, II); 15% (stage III) | |
| 5-year OS: 86% (stage I, II); 53% (stage III) | |||||
| 5-year DSS: 90% (stage I, II); 62% (stage III) | |||||
| Kotake, Japan, 2015 (13) | CME: 463 | – | 18.1 | 5-year OS: 91.9% (only pT2) | |
| Non-CME: 463 | – | 11.6 | 5-year OS: 90.6% (only pT2) | ||
| Storli, Norway, 2014 (14) | CME: 89 | – | 2.8 | 16.1 | 3-year LRR: 1.2%; 3-year OS: 88.1%; 3-year DFS: 82.1% |
| Non-CME: 105 | – | 8.8 | 14.8 | 3-year LRR: 2.9%; 3-year OS: 79.0%; 3-year DFS: 74.3% |
LRR, local recurrence rate; OS, overall survival; DFS, disease free survival; DSS, disease specific survival.